Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Psychedelic State(s) of America

Opinion

The Ibogaine Trial Nobody Can Join - PSA's Regulatory Dispatch, Vol. VI

Washington has committed its first money to testing ibogaine in Americans.

By Odette Hauke

Contributor

· 11 min read

The Ibogaine Trial Nobody Can Join - PSA's Regulatory Dispatch, Vol. VI

Fuel the Future of Psychedelic Journalism

Want to financially support original, independent reporting like this? You can! Donate at the link below.

Donate to PSA

ANALYSIS

“The Ibogaine Trial Nobody Can Join”

Psychedelic State(s) of America's Regulatory Dispatch, Vol. VI:

PSA’s Regulatory Dispatch, Vol. VI: The Ibogaine Trial Nobody Can Join
PSA’s Regulatory Dispatch, Vol. VI: The Ibogaine Trial Nobody Can Join

Washington has committed its first money to testing ibogaine in Americans. The safety rules drafted for that trial would screen out a large share of the people it is meant to help.

The public comment period on those rules closes Friday. Eighty comments are in so far, and not one of them asks the Agency to loosen the limit that does the excluding.

Here is the ibogaine trial the Food and Drug Administration (FDA) has in mind:

One person at a time, in a hospital bed, with "a defibrillator at the bedside" and a ventilator within reach. Continuous monitoring of the heart's rhythm from dosing until the electrical reset returns near where it started, which the Agency says could take 36 hours. An electrocardiogram, a reading of the heart's electrical activity, again at 48 hours before discharge. Two trained medical staff through the peak period, one a licensed mental health professional. Cognitive testing at the start, repeated for a year.

This is not like the other drugs in the psychiatric pipeline. One dose brings on a trip that can run past 24 hours, a waking but dreamlike state, and cardiac risks that can be fatal. The Agency's own notice ties it to a stretched electrical reset and to torsades de pointes, a heart rhythm that can kill. The protocol reads like one written for a cardiac procedure because, where the danger lies, that is what it is.

Then comes the part that decides who is eligible for that bed. A patient must be under 55, off any psychiatric medications, off methadone, and have a heart that resets faster than most hearts do. Each rule is defensible alone. Together they would turn away much of the population now crossing the border for this drug, including, on the heart rule alone, as many as a third of the women who would otherwise qualify.

Who is paying, and who is running it

On Nov. 12, the Department of Health and Human Services' innovation arm, the Advanced Research Projects Agency for Health, or ARPA-H, named the two medical research teams laying the groundwork. One is Beond, which runs an ibogaine clinic in Cancun and says it will hand over de-identified records from 250 patients it has treated, including heart tracings and side effects. The other is Mark Cuban Cost Plus Drug Company, which will work toward a version made in the United States. The federal commitment is "up to $4.9 million over five years," split between them and released in stages as each team hits an agreed target.

Beond is also at the center of this industry's hardest coverage. In August 2024, Rolling Stone reported the death of a 49-year-old American man at Beond in 2022, two days after his dose. The clinic declined to discuss the case, citing patient confidentiality, and said its medical team "adheres strictly to the established protocols and professional standards." This year The New York Times reported that patients were offered Xanax without regard to their medical histories, that staff at first would not tell a visiting psychiatrist his own ibogaine dose, and that a patient was interviewed by a co-founder soon after dosing. Beond's chief executive said the clinic takes complaints seriously and changes protocols when problems arise: the sedatives follow a patient's existing prescriptions and are a last resort, dose information comes after treatment on request, and interviews wait for a rest period and are shown to the patient first. He also said Beond stopped offering 5-MeO-DMT, a second psychedelic, because it was muddying the clinic's own effort to collect data on ibogaine outcomes.

That figure arrived in news coverage as the government funding ibogaine research. It averages under $1 million a year and does not pay for a trial. It pays for making the drug and for the safety data an investigational new drug application needs, the filing that makes human dosing legal. No such application has been filed. Texas separately holds $50 million for such trials, the largest public commitment to ibogaine in the country, though that program requires matching money from outside the state.

Two things follow. The earliest American safety data will lean on records from that clinic, worth knowing before anyone calls the result American evidence. And the trial's design is being settled now, on a schedule almost nobody is watching.

The comments on the trial design, and who sent them

On Oct. 6, the FDA published a request for information in the Federal Register, the government's daily journal of official notices, asking "clinicians, researchers, prospective sponsors, patients, and the public" what it had gotten wrong about the design. Answers go to docket FDA-2026-N-10429, the public record where every comment is posted and kept.

Everyone expected a fight, with the clinics, veterans and investors pushing ibogaine forward on one side and the FDA on the other. The drug reached Washington on the testimony of veterans who went abroad for treatment and an April executive order directing the government to speed psychedelic treatments, which names ibogaine specifically.

No fight came. Thirty-five comments were posted through Monday, and 45 more on Thursday, the day before the window shuts, which makes 80. Twenty-two ask the Agency to keep or strengthen its cardiac safeguards. None asks it to raise the 10 mg/kg dose. None asks it to loosen the heart-rhythm screen. The Agency had asked which cut-off on the heart's electrical reset would best protect participants, and proposed a number: 430 milliseconds. In the first 35 comments, 430 did not appear once. In the 45 that followed it appears exactly once, in a comment calling the threshold "appropriate for first-in-human cohorts." So where did they get this number from, and why does it matter?

Figure 1. Comments posted to Docket FDA-2026-N-10429 (n = 80): what each named and what each asked for. None asked the FDA to relax the cardiac exclusion or raise the 10 mg/kg ceiling.

Figure 1. Comments posted to Docket FDA-2026-N-10429, coded by what each one named and what each one asked for. The upper panel counts comments naming a specification the Agency proposed; the lower panel counts comments asking it to change something. Coding was done by a language model against a fixed codebook and audited by hand. n = 80, including the 45 posted on Nov. 19.

What 430 milliseconds does

Every heartbeat ends with an electrical reset, and a slow reset is the danger. That reset is the window in which certain drugs can tip a heart into a fatal rhythm. The FDA would turn away anyone whose reset before dosing is 430 milliseconds or longer.

Here is the trouble with 430. It is not the line between a healthy heart and a sick one. Among 46,129 people with no sign of heart disease, 98 in every 100 came in under 445 milliseconds. The Agency's cut-off is 15 milliseconds stricter than that. It does not screen out abnormal hearts. It screens out ordinary ones.

The cut-off also does not screen out men and women evenly. Women's hearts take longer to reset than men's, by 8 to 12 milliseconds at every age the trial would enroll. That puts the 430 line much closer to the middle of the women than of the men. Between 20 and 59 it would turn away 4% to 15% of men and 13% to 35% of women: at least twice as many women in every age band, and three times as many in their twenties and thirties.

Figure 2. Share of adults turned away by the FDA's proposed 430-millisecond cut-off, by sex and age: women 13% to 35%, men 4% to 15%, ages 20 to 59.

Figure 2. Share of adults whose heart reset before dosing would exceed the FDA's proposed cut-off of 430 milliseconds, by sex and age. Estimated from published percentiles in 486,014 primary-care electrocardiograms.

The Agency saw this coming. Its own notice asks what enrollment rules would manage the danger given known risk factors, and lists women among the "populations with known susceptibility to arrhythmia." It then proposes a threshold that turns away between an eighth and a third of them. One response to that vulnerability protects women by watching them more closely: continuous rhythm monitoring, correcting their blood chemistry before dosing, testing whether a magnesium drip blunts the effect. The other protects them by not enrolling them at all.

A second rule narrows the field in a different direction. As it is written, every participant would be tested for CYP2D6, the liver enzyme that converts ibogaine into noribogaine, the long-lived chemical that acts on the heart. Only fast and intermediate processors would be let in. The slow ones, who hold that chemical longest and are most exposed to its effects on the heart, would be kept out. That has nothing to do with sex, and it costs the study something critical: the people at highest risk will not appear in the safety data. The notice does not say how many people that excludes, and published frequencies of slow processing vary widely by ancestry. The records coming north to stand in for that missing group are heart tracings, side effects and symptom scores. Genotype is not among them.

A referendum on care

Ask the people who did show up what they want, and the loudest answer is more watching and more aftercare, not more access. The comments came mostly from individuals describing the unregulated world of ibogaine treatment outside the United States. The New York Times counted at least 40 clinics in Mexico offering ibogaine, where a decade ago there were almost none. The Times also reported on a study in JAMA of 49 advertised psychedelic clinics and retreats that found fewer than half employed a medical professional, and about one in 10 had anyone trained for emergencies. Eleven commenters describe treatment abroad, six of those in Mexico. Neither funded team submitted a comment, nor did the Texas consortium, nor any cardiology, addiction medicine or psychiatric body. That left the 430 line, the number at the center of the design, to whoever turned up.

The sharpest objection came from a commenter who identified itself as an AI. "I am an AI agent, not a clinician or a researcher," it began, before taking issue with the enzyme rule: "A trial designed to exclude the most exposed genotype cannot later support a conclusion about it." Five of the 80 posted comments mention that enzyme, which is to say the rule that decides whose safety this study can describe drew almost no scrutiny.

Twenty-two comments ask for aftercare, 19 for long-term follow-up, 19 for wider eligibility. A former Marine aviator warned that the trials should not become so narrow that they settle whether ibogaine is safe "while failing to capture whether people actually rebuild their lives."

The design also has a rule for the worst case. If a participant develops new suicidal thoughts or behavior after the acute effects wear off, dosing pauses across the whole study for review by the trial's safety review committee, its independent data safety monitoring board and the FDA. By then the participant is home. A chaplaincy founder called that the gap: meticulous about the hospital stay, silent about the weeks after. "It does not say who supports participants between discharge and those assessments," he wrote. For people with opioid use disorder, that window is also when their tolerance has collapsed, the overdose risk the FDA raised in its own questions and then answered with a sentence saying the patient "may be escorted home by a trusted adult."

If you or someone you know is struggling, call or text 988 in the U.S. to reach the Suicide & Crisis Lifeline.

Deaths after ibogaine have been reported and autopsied for decades. What those cases cannot produce is a death rate: there is no official tally of injuries, deaths and adverse experiences at psychedelic clinics abroad. Ibogaine therapy offerings in Mexico differ in dose, formulation and purity, and some involve other drugs taken alongside, the psychedelic 5-MeO-DMT among them; the FDA says the published literature lacks the detail to pin down dose, quality, purity and potency. In 1993, an FDA advisory committee asked whether a dose exists high enough to help and low enough to spare the brain. The Agency's written answer, in this year's notice, is that those questions "remain relevant today."

One commenter wrote that the best thing the government could do is "believe in the plant medicine." Twenty-one of the 80 comments come from patients and their families. As real as their conviction is, so are the risks. A drug that saves one person and might kill another at the same dose is not being merciful to the first or cruel to the second. The trial being designed now is the first serious American attempt to find out which is which.

What happens next is already set. Anyone can still write to the Agency through regulations.gov until 11:59 p.m. EST this Friday, Nov. 20, and the notice warns that "late, untimely filed comments will not be considered." The backlog cleared on Thursday, when 45 comments went up at once. After Friday the Agency weighs what it received before issuing guidance, and the two funded teams work through five years of payment targets before a single American is dosed. The open question is not whether the trial is careful. It is whether a trial this careful can describe the people already taking the drug.

Author disclosure. Odette Hauke is an epidemiologist and regulatory scientist advising sponsors developing oncology, rare disease and psychedelic drugs, including LSD, MDMA, DMT and ibogaine. She was previously Associate Director of Regulatory Affairs at atai Beckley, which Eli Lilly acquired in September 2026, and a consultant to its ibogaine, R-MDMA and DMT programs.

Editor's disclosure. Noah Daly, Psychedelic State(s) of America's Managing Editor-at-Large, co-wrote The New York Times article cited in this column.

Enjoyed this column? Subscribe to Psychedelic State(s) of America and share this column with someone who should read it.

Support independent journalism

The PSA Media Fund

Psychedelic State(s) of America isn’t another news outlet — it’s a vessel to help the fantastic independent psychedelic and cannabis media organizations that already exist do more of what they do best. Our coverage is reader-funded, and your support keeps news, commentary, and education on psychedelic policy free for everyone.

Donate to PSA

Until next time,
The Psychedelic State(s) of America Team

Read our Editorial StandardsRequest a correction

You read to the end

Get PSA's Regulatory Dispatch in your inbox

Free to read. Free to subscribe.

About the author

Odette Hauke

Regulatory Dispatch writer

Odette Hauke, M.S., writes Regulatory Dispatch for Psychedelic State(s) of America. An epidemiologist and regulatory scientist, she is the founder of Odette Alina LLC, an independent consultancy for psychedelic, controlled-substance, CNS, rare disease, and botanical drug programs. Over more than thirteen years she has worked directly with FDA, DEA, EMA, MHRA, and Health Canada, and she served as regulatory lead for ibogaine, R-MDMA, and DMT programs at AtaiBeckley. In September 2026 she spoke on ibogaine cardiac risk at FDA’s public hearing on the therapeutic use of psychedelic drugs. She is a regulatory science and policy contributor at Cascades Analytics. Her analysis has also appeared in Law360, Clinical Leader, Drug Discovery Online, and the American Bar Association’s Health eSource, and she has been quoted in POLITICO and Nature. A 2025 Women in Bio Impact Scholar, she holds an M.S. in regulatory affairs from Northeastern University, a B.S. in epidemiology from CUNY Hunter College, and a certificate in psychedelic science and medicine from Johns Hopkins University. She is also an essayist and an exhibiting artist working in painting, photography, and film.

Related commentary